FDA Alerts Providers to Recall of Compounded Drug Products
Coastal Meds LLC, which compounds drugs as an outsourcing facility, has voluntarily recalled all of its products marketed as sterile due to visible particles in some of the drug vials for injection, the Food and Drug Administration announced Friday. Health care providers should immediately quarantine and not administer any Coastal Meds sterile drug products intended for injection, FDA said. The agency encourages health care professionals and patients to report any adverse reactions or quality problems to the MedWatch program.
Related News Articles
Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program. “When…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…